Arsenic (As) contamination in an ecosystem has been a serious threat for the ecosystem as well as human health. Thus, the present study was established an eco-friendly remediation of As by using As resistant Rhodobacter sp. Accordingly, the growth of Rhodobacter sp. in As stress environment was assessed. Expectedly, enhanced growth order of the Rhodobacter sp., under As stress was found to be control >50 > 100 > 200 > 300 > 400 > 500 mg/L of As. In addition, the present study explored the influence of various light sources (Yellow, light blue, red, green and white) on growth and As removal mechanisms of Rhodobacter sp. The growth profile of the bacteria indicated that the light blue source showed an enhanced growth at 72 h of incubation. Based on optimization experiments, an increased As removal percentage rate was found to be at 87.5% at pH 7.0, 3% of glucose, 1% of citrate supplemented in the medium. The As resistant genetic pattern for arsenic transformation, the genes arsenate reductase (arsC), arsenite oxidase (aio) was investigated. To study the transcript level expression of arsC and aio genes were performed after exposure to different concentrations of As (50, 100, 150, and 200 mg/L) at different time intervals (24, 48, 72 and 96 h). The results showed that both arsC and aio were up regulated from 24 to 72 h and the down regulation was observed at 96 h. The obtained results indicated that the Rhodobacter sp., possess significant AS tolerance and removal potential would make it is a noteworthy candidate for future As remediation practices.

20 Aug 2020·Anti-Cancer Agents in Medicinal ChemistryQ4 · MEDICINE

Synthesis, Biological and Computational Evaluation of Novel 2,3-dihydro-2-aryl-4-(4- isobutylphenyl)-1,5-benzothiazepine Derivatives as Anticancer and Anti-EGFR Tyrosine Kinase Agents

Q4 · MEDICINE

Article

Author: Prasad, Yejella R. ; Nissankararao, Srinath ; Shahanaaz, Shaik ; Shaik, Afzal B.

Background:Despite the availability of a variety of chemotherapeutic agents, cancer is still one of the leading causes of death worldwide because of the problems with existing chemotherapeutic agents like objectionable side effects, lack of selectivity, and resistance. Hence, there is an urgent need for the development of novel anticancer agents with high usefulness, fewer side effects, devoid of resistance and superior selectivity.Objective:The objective of this study is to synthesize a series of novel 1,5-benzothiazepine derivatives and evaluate their anticancer activity employing biological and computational methods.Methods:Twenty new benzothiazepines (BT1-BT20) were prepared by condensing different 1-(4- isobutylphenyl)ethanone chalcones with 2-amiothiophenol and evaluated for their anticancer activity by MTT assay against three cell lines including HT-29 (colon cancer), MCF-7 (breast cancer) and DU-145 (prostate cancer). These compounds were also tested for their inhibitory action against EGFR (Epidermal Growth Factor Receptor) tyrosine kinase enzyme by taking into account of their excellent action against colon and breast cancer cell lines. Further, the structural features responsible for the activity were identified by Pharmacophorebased modelling using Schrodinger’s PHASETM software.Results:Among the 20 benzothiazepine derivatives, three compounds viz., BT18, BT19 and BT20 exhibited promising activity against the cell lines tested and the activity of BT20 was more than the standard methotrexate. Again the above three compounds showed excellent inhibitory activity with the percentage inhibition of 64.5, 57.3 and 55.8 respectively against EGFR (Epidermal Growth Factor Receptor) tyrosine kinase. PHASE identified a five-point AHHRR model for the proposed activity and the computational studies provided insights into the structural requirements for the anticancer activity and the results were consistent with the observed in vitro activity data.Conclusion:These novel benzothiazepines will be useful as lead molecules for the further development of new cancer therapies against colon and breast cancers.

01 Jun 2019·International Journal of Biological MacromoleculesQ1 · CHEMISTRY

Effect of blue light on growth and exopolysaccharides production in phototrophic Rhodobacter sp. BT18 isolated from brackish water

Q1 · CHEMISTRY

Article

Author: Selvankumar, T ; Kamala-Kannan, S ; Govarthanan, M ; Srinivasan, P ; Mythili, R ; Kim, H

Rhodobacter sp. BT18, a phototrophic salt-resistant bacterium, was isolated from brackish water and screened for the production of exopolysaccharides (EPS). The effect of different light sources on the growth of Rhodobacter sp. BT18 was investigated. The effect on the growth order was found to be blue > white > green > red > yellow > dark. Based on Box-Behnken design, the studied variables (pH 7.0, 35 °C, and 30% of sucrose concentration under 60 h of incubation with blue light illumination) were found to be ideal for the maximum production of EPS (582.5 mg/L). Scanning electron microscopy images revealed the porous nature of EPS. Fourier transform spectroscopy and X-ray diffraction were applied to study the functional groups and the crystalline nature of the EPS, respectively. The emulsification index of the EPS was >75% and the maximum flocculating activity was about 75.4% at 30 mg/L concentration of EPS. In addition, EPS showed effective arsenic (64%) and lead (51%) chelating activities in liquid solutions. The multiple environmental applications of the EPS produced by Rhodobacter sp. BT18 make it be a promising alternative for emulsification, flocculation and metal removal in various industries.

100 Deals associated with BT-18

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Preclinical	EE	Genecode Health Pvt Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

BT-18

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation